Cooke Kenneth R, Luznik Leo, Sarantopoulos Stefanie, Hakim Frances T, Jagasia Madan, Fowler Daniel H, van den Brink Marcel R M, Hansen John A, Parkman Robertson, Miklos David B, Martin Paul J, Paczesny Sophie, Vogelsang Georgia, Pavletic Steven, Ritz Jerome, Schultz Kirk R, Blazar Bruce R
Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland.
Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland.
Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234. doi: 10.1016/j.bbmt.2016.09.023. Epub 2016 Oct 3.
Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality and disability in allogeneic hematopoietic cell transplantation recipients and a major obstacle to improving outcomes. The biology of chronic GVHD remains enigmatic, but understanding the underpinnings of the immunologic mechanisms responsible for the initiation and progression of disease is fundamental to developing effective prevention and treatment strategies. The goals of this task force review are as follows: This document is intended as a review of our understanding of chronic GVHD biology and therapies resulting from preclinical studies, and as a platform for developing innovative clinical strategies to prevent and treat chronic GVHD.
慢性移植物抗宿主病(GVHD)是异基因造血细胞移植受者晚期非复发死亡率和致残率的主要原因,也是改善治疗结果的主要障碍。慢性GVHD的生物学机制仍然不明,但了解引发和推动疾病进展的免疫机制基础对于制定有效的预防和治疗策略至关重要。本特别工作组综述的目标如下:本文旨在回顾我们对慢性GVHD生物学以及临床前研究所得出的治疗方法的理解,并作为制定预防和治疗慢性GVHD的创新临床策略的平台。